TY - JOUR
T1 - Estrogen receptor-negative invasive breast cancer
T2 - Imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression
AU - Wang, Yingbing
AU - Ikeda, Debra M.
AU - Narasimhan, Balasubramanian
AU - Longacre, Teri A.
AU - Bleicher, Richard J.
AU - Pal, Sunita
AU - Jackman, Roger J.
AU - Jeffrey, Stefanie S.
N1 - (c) RSNA, 2008.
PY - 2008/2
Y1 - 2008/2
N2 - Purpose: To prospectively determine if estrogen receptor (ER)-negative human epidermal growth factor receptor type 2 (HER2)-positive and ER-negative HER2-negative breast cancers have distinguishing clinical and imaging features with use of retrospectively identified patients and tissue samples. Materials and Methods: This HIPAA-compliant study was institutional review board approved. Informed consent was obtained from living patients and waived for deceased patients. Mean patient age at diagnosis was 53 years (range, 31-84 years). Clinical history; histopathologic, mammographic, and breast sonographic findings; and HER2 status as determined with immunohistochemistry or fluorescent in situ hybridization were evaluated in 56 women with ER-negative breast cancer. Imaging appearances and clinicopathologic characteristics were correlated with tumor HER2 status. P < .05 indicated a significant difference. Results: Lesion margins on mammograms (P = .028) and sonograms (P = .023), calcifications on mammograms (P = .003), and clinical cancer stage at diagnosis (P = .029) were significantly associated with HER2 status. In contrast to ER-negative HER2-negative tumors, ER-negative HER2-positive tumors were more likely to have spiculated margins (56% vs 15%), be associated with calcifications (65% vs 21%), and be detected at a higher cancer stage (74% vs 57%). Conclusion: Biologic diversity of cancers may manifest in imaging characteristics, and, conversely, studying the range of imaging features of cancers may help refine current molecular phenotypes.
AB - Purpose: To prospectively determine if estrogen receptor (ER)-negative human epidermal growth factor receptor type 2 (HER2)-positive and ER-negative HER2-negative breast cancers have distinguishing clinical and imaging features with use of retrospectively identified patients and tissue samples. Materials and Methods: This HIPAA-compliant study was institutional review board approved. Informed consent was obtained from living patients and waived for deceased patients. Mean patient age at diagnosis was 53 years (range, 31-84 years). Clinical history; histopathologic, mammographic, and breast sonographic findings; and HER2 status as determined with immunohistochemistry or fluorescent in situ hybridization were evaluated in 56 women with ER-negative breast cancer. Imaging appearances and clinicopathologic characteristics were correlated with tumor HER2 status. P < .05 indicated a significant difference. Results: Lesion margins on mammograms (P = .028) and sonograms (P = .023), calcifications on mammograms (P = .003), and clinical cancer stage at diagnosis (P = .029) were significantly associated with HER2 status. In contrast to ER-negative HER2-negative tumors, ER-negative HER2-positive tumors were more likely to have spiculated margins (56% vs 15%), be associated with calcifications (65% vs 21%), and be detected at a higher cancer stage (74% vs 57%). Conclusion: Biologic diversity of cancers may manifest in imaging characteristics, and, conversely, studying the range of imaging features of cancers may help refine current molecular phenotypes.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor/metabolism
KW - Breast Neoplasms/classification
KW - Calcinosis/classification
KW - Female
KW - Humans
KW - Male
KW - Mammography/methods
KW - Middle Aged
KW - Receptor, ErbB-2/metabolism
KW - Reproducibility of Results
KW - Sensitivity and Specificity
UR - http://www.scopus.com/inward/record.url?scp=39549101230&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000252796300005&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1148/radiol.2462070169
DO - 10.1148/radiol.2462070169
M3 - Article
C2 - 18180338
SN - 0033-8419
VL - 246
SP - 367
EP - 375
JO - Radiology
JF - Radiology
IS - 2
ER -